I BET on anti-FGFR to fight cancer resistance

EMBO Mol Med. 2019 Feb;11(2):e10116. doi: 10.15252/emmm.201810116.

Abstract

L. Altucci and R. Benedetti discuss the study by Chua et al (in this issue of EMBO Molecular Medicine), in which co‐targeting of FGFR signaling increases the responses of metastatic uveal melanoma to BET inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Fibroblast Growth Factor 2
  • Humans
  • Melanoma*
  • Uveal Neoplasms*

Substances

  • Fibroblast Growth Factor 2

Supplementary concepts

  • Uveal melanoma